dexamethasone + haloperidol

Dexamethasone + haloperidol is a combination of two pharmaceutical agents used primarily for the prevention and management of postoperative nausea and vomiting (PONV) and as an antiemetic regimen in patients undergoing chemotherapy or surgery. Dexamethasone is a synthetic glucocorticoid corticosteroid with potent anti-inflammatory and immunosuppressant properties, acting mainly through activation of the glucocorticoid receptor to modulate gene expression, inhibit pro-inflammatory mediators, and suppress immune responses[6][8]. Haloperidol is a first-generation (typical) antipsychotic that acts predominantly as an antagonist at dopamine D2 receptors in the central nervous system, particularly within the chemoreceptor trigger zone (CTZ), providing both antipsychotic and antiemetic effects[4][9]. The combination has been shown to reduce the incidence of vomiting after surgery more effectively than dexamethasone alone in high-risk patients[1], though its efficacy as an antiemetic during chemotherapy may be limited compared to other regimens[2]. This combination may be compounded for use in palliative care settings for symptom control.